



Report to the Chairman, Subcommittee
on Labor, Health and Human Services,
Education, and Related Agencies,
Committee on Appropriations, House
of Representatives

March 2014

NATIONAL INSTITUTES OF HEALTH

Research Priority Setting, and Funding Allocations across Selected Diseases and Conditions

GAO Highlights

Highlights of [GAO-14-246](#), a report to the Chairman, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, Committee on Appropriations, House of Representatives

Why GAO Did This Study

NIH is the nation's leader in sponsoring and conducting biomedical research. In fiscal year 2012, NIH had a budget of almost \$31 billion, over 80 percent of which was used to fund extramural research that supports scientists and research personnel working at universities, medical schools, and other research institutions. Twenty-four of NIH's 27 ICs that support extramural research are focused on particular diseases, conditions, or research areas, and these ICs have their own appropriations. Decisions about which projects are funded are made by these individual ICs. NIH reports funding for 235 research, condition, and disease categories in RCDC.

GAO was asked to review NIH funding related to leading diseases and health conditions. GAO examined (1) how research priorities are set at NIH, and (2) NIH allocations of research funding across selected diseases and conditions. For five ICs—National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; and National Institute of General Medical Sciences—GAO reviewed documents and interviewed IC officials about priority setting. GAO reviewed NIH fiscal year 2012 funding reported by RCDC for 40 research, condition, and disease categories related to the leading causes of death in the United States and globally, and the most prevalent chronic diseases and conditions in the United States.

View [GAO-14-246](#). For more information, contact Linda T. Kohn at (202) 512-7114 or kohnl@gao.gov.

March 2014

NATIONAL INSTITUTES OF HEALTH

Research Priority Setting, and Funding Allocations across Selected Diseases and Conditions

What GAO Found

Individual institutes and centers (ICs) at the National Institutes of Health (NIH) set their own research priorities, and GAO found that the five selected ICs—awarding the largest amount of research funding—that it reviewed did so considering similar factors and using various priority-setting approaches. Agency officials stated that the ICs' mission and appropriations inform priority-setting approaches. Some IC officials noted that because the costs of potential research projects generally exceed the available appropriation, the ICs must prioritize among research projects. In priority setting, IC officials reported taking into consideration scientific needs and opportunities, gaps in funded research, the burden of disease in a population, and public health need, such as an emerging public health threat like influenza that needs to be addressed. While each IC GAO examined had its own approach for setting priorities, they all considered the input of stakeholders, including the scientific community, and used some similar strategies. All five ICs developed strategic plans, though the process varied by IC. Some ICs also used annual planning activities in various forms, which then guided funding opportunity announcements. All five ICs also conducted reviews and evaluations of their research portfolios to ensure that their priorities align with scientific opportunities, research gaps, and emerging science. In addition to these efforts at the IC level, agency officials told GAO that the NIH Office of the Director provides leadership and coordinates priority setting activities, especially for those activities that involve multiple ICs.

NIH reported funding levels that varied widely for the 40 different Research, Condition, and Disease Categorization system (RCDC) categories GAO examined that correspond to the leading causes of death and the most prevalent chronic conditions. For example, NIH reported actual fiscal year 2012 funding levels ranging from \$13 million for projects in the fibromyalgia category to more than \$5.6 billion for projects in the cancer category. Although these categories are part of NIH's RCDC, which is used to categorize the research activities across the agency, agency officials said that the system cannot estimate a total, non-duplicated amount of funding that is specific to a given disease or condition. This is because RCDC categories are neither mutually exclusive nor exhaustive. For example, projects may be included in multiple RCDC categories, some categories are related to each other and therefore some categories may also be included within another, and funding for all diseases is not captured in the system. While RCDC is NIH's official system for reporting research funding across the ICs, two of the five ICs that GAO reviewed—the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases—had their own systems for tracking their funding, which allowed them to provide more detailed information than that available from RCDC. For example, NCI has a publicly available website that specifies funding for more than 40 specific cancer types as well as almost 50 research topics that are not disease-specific. Funding for individual projects may be separated for specific studies into those cancer types. According to officials, the system enhances NCI's ability to plan and monitor its scientific investment.

The Department of Health and Human Services provided technical comments, which GAO incorporated as appropriate.

Contents

Letter		1
	Background	3
	Individual Institutes and Centers Set Their Own Research Priorities Using a Variety of Approaches, Including Strategic Planning, Annual Planning, and Review of Research Portfolios	6
	NIH Funding Levels Varied Widely For Selected Categories of Research, Conditions, and Diseases Corresponding to the Leading Causes of Death and Chronic Conditions	11
	Agency Comments	15
Appendix I	Studies about the Relationship between Research Funding and Burden of Disease	16
Appendix II	Leading Causes of Death and Chronic Conditions and their Corresponding National Institutes of Health Categories	18
Appendix III	GAO Contact and Staff Acknowledgments	25
Tables		
	Table 1: Reported Funding for Categories in NIH's Research, Condition, and Disease Categorization System (RCDC) Corresponding to Leading Causes of Death and Chronic Conditions, Fiscal Year 2012	12
	Table 2: Leading Causes of Deaths in the United States, 2011	19
	Table 3: Leading Causes of Deaths Globally, 2010	20
	Table 4: Chronic Disease Prevalence for Adults, United States	21
	Table 5: Diseases and Conditions that Represent the Leading Causes of Death and Most Prevalent Chronic Diseases and Conditions and Corresponding Categorization	22

Abbreviations

AIDS	acquired immunodeficiency syndrome
CDC	Centers for Disease Control and Prevention
DALY	disability-adjusted life years
HHS	Department of Health and Human Services
HIV	human immunodeficiency virus
IC	institute and center
ICD-10	International Classification of Diseases
NCI	National Cancer Institute
NHLBI	National Heart, Lung, and Blood Institute
NIAID	National Institute of Allergy and Infectious Diseases
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIGMS	National Institute of General Medical Sciences
NIH	National Institutes of Health
OD	Office of the Director
RCDC	Research, Condition, and Disease Categorization system
YLL	years of life lost to premature death

This is a work of the U.S. government and is not subject to copyright protection in the United States. The published product may be reproduced and distributed in its entirety without further permission from GAO. However, because this work may contain copyrighted images or other material, permission from the copyright holder may be necessary if you wish to reproduce this material separately.



March 31, 2014

The Honorable Jack Kingston
Chairman
Subcommittee on Labor, Health and Human Services,
Education, and Related Agencies
Committee on Appropriations
House of Representatives

Dear Mr. Chairman:

The National Institutes of Health (NIH) is the nation's leader in sponsoring and conducting biomedical research. In fiscal year 2012, NIH, an agency of the Department of Health and Human Services (HHS), had a budget of almost \$31 billion, over 80 percent of which was used to fund extramural research that supports scientists and research personnel working at universities, medical schools, and other research institutions. NIH also funds intramural research performed by NIH scientists in NIH laboratories. To fulfill its mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, NIH funds research related to life processes and many diseases and conditions, including those that are among the leading causes of death both in the United States and globally.¹

The range of research that NIH funds is reflected in its organization, consisting of the Office of the Director (OD) and 27 institutes and centers (IC). The ICs that support extramural research are focused on particular diseases, conditions, or research areas and are supported by their own budget, mission, and staff. Each IC makes final decisions on which projects to fund or conduct contingent on the available appropriation or funding.² Given NIH's role in biomedical research, its broad mission, and

¹According to the Centers for Disease Control and Prevention, leading causes of death in the United States in 2011 include diseases of the heart, malignant neoplasms, chronic lower respiratory diseases, cerebrovascular disease, and accidents. The most prevalent chronic diseases and conditions include obesity, chronic joint symptoms, hypertension, untreated dental caries, and arthritis.

²NIH funds research projects through a range of mechanisms, such as research grants and contracts. For the purposes of this report, we refer to relevant NIH-funded research as "projects" and do not distinguish between the different types of awards.

the size of its budget, Congress and researchers have had long-standing interest in how NIH establishes research priorities and how those priorities guide the allocation of its resources, particularly in relation to various diseases and conditions.

You requested that we provide information on federally funded research related to diseases and health conditions that are the leading causes of death or the most prevalent chronic conditions. In this report, we describe (1) how research priorities are set at NIH, and (2) NIH allocations of research funding across selected diseases and conditions.

In addition, appendix I of this report summarizes key findings from published studies about the relationship between the extent of research funded and the burden of diseases being researched, both at NIH and in other countries. The research used measures of disease burden, such as the prevalence of disease or conditions in a population, hospitalization rates, and mortality associated with a particular disease.

To describe how research priorities are set at NIH, we reviewed relevant laws and agency guidance, including documents that outline methods for setting priorities for research funding from the five ICs that awarded the largest amount of research funding in fiscal year 2012.³ The five ICs are National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and National Institute of General Medical Sciences (NIGMS). We also interviewed officials from OD and those five ICs about their processes for setting priorities for research funding. We did not evaluate the appropriateness of the IC's processes for setting priorities for research funding.

To describe research funding allocations across selected diseases and conditions, we first identified the leading causes of death in the United States, the leading causes of death globally, and the most prevalent chronic conditions for adults in the United States. We then identified the categories within NIH's Research, Condition, and Disease Categorization system (RCDC) that best matched each disease and condition we

³Funding by the five selected ICs constituted approximately 57 percent of total research grant funding.

selected, and we confirmed these matches with NIH. (See app. II for a more detailed description of our methodology for identifying the leading causes of death, the most prevalent chronic conditions, and their corresponding NIH research, condition, and disease categories.) We reviewed publically available RCDC funding data from fiscal year 2012 for those categories. We also interviewed NIH officials responsible for RCDC to understand the data gathered and reported on. We determined that the data were sufficiently reliable for the purposes of this review.

We conducted our work from April 2013 to March 2014 in accordance with generally accepted government auditing standards. Those standards require that we plan and perform the audit to obtain sufficient, appropriate evidence to provide a reasonable basis for our findings and conclusions based on our audit objectives. We believe that the evidence obtained provides a reasonable basis for our findings and conclusions based on our audit objectives.

Background

NIH's Organization

As the central office for NIH, OD establishes NIH policy and broad themes for the agency to pursue, such as ensuring a sustainable scientific workforce, based on national needs and scientific opportunities. In addition, the OD is responsible for coordinating the programs and activities that span NIH components, particularly research initiatives and issues involving more than 1 of the 27 ICs. OD is also responsible for ensuring that scientifically-based strategic planning is implemented in support of research priorities, and that NIH's resources are sufficiently allocated for research projects identified in strategic plans. NIH conducts and sponsors biomedical research through its ICs, each of which is charged with a specific mission. ICs' missions generally focus on a specific disease, a particular organ, or a stage in life, such as childhood or old age. The ICs support, plan, and manage their own research programs in keeping with OD policy and priorities. Within an IC, there can be a number of offices, centers, and divisions that focus on specific aspects of the IC's mission. For example, NCI has a Division of Cancer Epidemiology and Genetics, as well as a Division of Cancer Treatment and Diagnosis.

Extramural and Intramural Research Supported by NIH

ICs accomplish their missions chiefly through extramural and intramural research. Extramural research accounted for more than 80 percent of NIH's budget in fiscal year 2012. This research is conducted at 2,500 universities, medical schools, research organizations, and companies who are awarded extramural research grants or extramural research and development contracts through NIH's competitive process. Twenty-four of the 27 ICs fund extramural research projects, and these ICs make final decisions on which extramural research projects to fund following a standard peer review process.⁴ Most IC extramural funding is provided for what NIH considers "unsolicited" research and research training projects for which applications are submitted in response to broad funding opportunity announcements that span the breadth of the NIH mission. In addition, to encourage and stimulate research and the submission of research applications in specific areas, many ICs will issue solicitations that are more narrow in scope in the form of program announcements, requests for applications, and requests for proposals.⁵ When reviewing applications for extramural research projects, NIH follows a process of peer review, established by law.⁶ This peer review system has two sequential levels of peer review. According to NIH officials, the first level involves panels of experts to assess the scientific merit of the proposed science. The second level involves panels of experts and leaders of non-science fields including patient advocates that, in addition to scientific merit, also consider the IC's mission and strategic plan goals, public health needs, scientific opportunities, and portfolio balance. After NIH's

⁴These 24 ICs receive specific appropriations, distinct from others available to NIH, such as the Office of the Director.

⁵A program announcement identifies areas of increased priority and/or emphasis for a specific area of science. A request for application identifies an area for which one or more NIH institutes have set aside funds for awarding grants. A request for proposal solicits contract proposals.

⁶See 42 U.S.C. §§ 282(b)(9) (the Director of NIH must ensure that NIH research undergoes peer review and advisory council review); 289a(a) (peer review); 289a-1(a)(2) (advisory council review).

peer review process is concluded, IC directors make extramural funding decisions.⁷

Intramural research, which accounts for approximately 10 percent of NIH's budget, is conducted by NIH scientists in NIH laboratories. This includes about 5,300 scientists and technical support staff who are employees, and another 5,000 young scientists at various stages of research training who come to NIH for a few years to work as non-employee trainees, including 3,800 postdoctoral fellows. All but 3 of the 27 ICs have an intramural research program, but the size, structure, and activities of the programs vary greatly.⁸

NIH's Research, Condition, and Disease Categorization System

In January 2007, Congress directed NIH to establish an electronic system to categorize the research grants and activities of OD and all the ICs.⁹ In response, NIH created RCDC. Implemented in February 2008, RCDC uses a computer-based text-mining tool that recognizes words and phrases in project descriptions in order to assign NIH projects to at least one of 235 categories of diseases, conditions, and research areas that

⁷NIH may not approve or fund any application unless it has been recommended for approval by a majority of the members of the initial peer review group and a majority of the voting members of an IC's advisory council. The initial peer review groups recommend applications for approval by means of a scoring system. 42 U.S.C. § 289a-1(a)(2). In general, advisory councils (or advisory boards) consist of no more than 18 voting members, two-thirds of whom are scientists in the research areas of the IC and one-third of whom are leaders of non-science fields. Advisory councils also include ex officio members who are nonvoting.

⁸Given their missions, the Fogarty International Center, the Center for Information Technology, and the Center for Scientific Review do not have an intramural research component. For example, the Center for Scientific Review serves as the portal for NIH grant applications and their review for scientific merit.

⁹National Institutes of Health Reform Act of 2006, Pub. L. No. 109-482, § 104, 120 Stat. 3675, 3689 (2007) (adding § 403B to the Public Health Service Act, codified at 42 U.S.C. § 282b). The House committee of reference indicated that this language was intended to address a recommendation made in an Institute of Medicine report to standardize data and information management systems by creating a comprehensive electronic reporting system that would catalogue all of the research activities of the NIH in a standardized format. H. Rep. No. 109-687, at 4 – 5 (2006), referring to Institute of Medicine, *Responding to Health Needs and Scientific Opportunity: The Organizational Structure of the National Institutes of Medicine*, (Washington, D.C.; Oct. 16, 1984).

were developed for reporting to Congress and the public.¹⁰ NIH officials said that RCDC serves as NIH's primary computerized reporting process to categorize its research funding.¹¹ The system includes reporting tools that can be used to generate publically-available, web-based reports on total funding amounts for the research projects related to each RCDC category.

Individual Institutes and Centers Set Their Own Research Priorities Using a Variety of Approaches, Including Strategic Planning, Annual Planning, and Review of Research Portfolios

Individual ICs at NIH set their own research priorities, and we found that the five selected ICs we reviewed did so considering similar factors and using various priority-setting approaches. Officials at all five of the ICs stated that their mission and available appropriations inform priority setting approaches. Officials at one IC noted that their IC's mission provides context related to why the IC was developed initially and insight into the emerging areas of research. Officials stated that an IC's appropriations not only set funding parameters, but may also influence priority setting if the appropriations include mandated spending by Congress for a specific disease.¹² Some IC officials noted that because the costs of potential research projects generally exceed the available appropriation, the ICs generally must prioritize among research projects. In priority setting, IC officials also reported taking into consideration scientific needs and opportunities, gaps in funded research, the burden of disease in a population, and public health need, such as an emerging public health threat that needs to be addressed, like influenza.

¹⁰The text mining tool is used in conjunction with NIH definitions—a list of terms and concepts selected by NIH experts to define a research category—to match research projects to categories. Projects may fall into one or more categories. There are additional categories that are not reported publicly for issues such as climate change for a total of approximately 270 categories.

¹¹RCDC tracks projects funded by three different types of NIH funding: extramural research grants, research and development contracts, and intramural research conducted in NIH's own laboratories and clinics. Information on funding totals and projects within each category is available on the NIH website. See "Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)" accessed November 25, 2013, http://www.report.nih.gov/categorical_spending.aspx.

¹²According to NIH officials, an example of an appropriation that includes mandated spending for a specific disease is for type I diabetes.

While individual ICs used different approaches to priority setting, all five selected ICs we reviewed reported using some combination of strategic planning, annual planning, and periodic review and evaluation of their research portfolios as part of their approach to priority setting.

Strategic planning: All five ICs we interviewed developed strategic plans—consistent with law and NIH policy—to set priorities and goals for research funding.¹³ According to officials at selected ICs, the development of these plans is guided by various processes at each IC. Although these processes vary by IC, they include an opportunity to solicit input from stakeholders, including the scientific community, as well as review by IC staff and leadership. Examples of IC strategic planning activities include the following:

- NIAID used a framework organized around various scientific areas that encompassed its research to develop the strategic plans it published in 2000, 2008, and 2013.¹⁴ When developing the plans, NIAID convened groups of NIAID subject matter experts for each scientific area and considered input offered by external organizations and scientists to guide the process. The experts deliberated priorities identified for each scientific area and suggested revisions to the draft plan. For example, officials stated that NIAID has seen a shift in the emphasis on research efforts related to human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) from studying single-drug therapy to the current focus on finding improved HIV treatments and tools for preventing infection. This new focus was then incorporated as part of the strategic plan published in 2013. Draft strategic plans were reviewed by the NIAID Advisory Council.¹⁵ After a final review by the director of NIAID, the finalized plans were published on NIAID's web site.

¹³See 42 U.S.C. § 282(b)(5).

¹⁴For example, NIAID included four scientific areas of emphasis in the 2013 strategic plan: human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS); infectious diseases (non-AIDS), including emerging and re-emerging disease and biodefense; allergy, immunology, and immune-mediated diseases; and global health research.

¹⁵Each IC's Advisory Council not only conducts the second level of NIH's peer review but also offers advice and recommendations on policy and program development, program implementation, evaluation, and other matters of significance to the mission and goals of the IC.

-
- NHLBI officials said that, as of November 2013, the IC was revising the strategic plan it published in 2007 and part of its strategic planning process under the direction of a new director appointed in 2012. As part of the revised process, NHLBI created the Strategic Investment and Management Steering Committee that will help establish strategic goals as well as advise leadership about whether proposed activities are consistent with the IC's strategic plan. Officials stated that the strategic planning process will engage both NHLBI scientific staff as well as the larger extramural community because they are knowledgeable about research gaps within their respective fields. Further, NHLBI officials stated that input provided by stakeholders also helps to inform development of disease-specific planning documents, such as one for asthma and another on sleep disorders.

Annual planning activities: In addition to the development of strategic plans, some IC officials we interviewed told us that they conduct annual planning activities as a part of their process to set priorities for research funding. They told us that these annual planning activities address ongoing and emerging needs. While the processes vary across the ICs in terms of the level of structure and formality, officials stated that during the annual planning process these ICs typically consider factors such as scientific needs, research gaps, scientific opportunities, public health needs, and the need to balance the various types of research conducted to address all areas of the mission. Examples of annual planning activities include the following:

- NIAID uses an annual planning process to develop and select initiatives that address special needs, gaps, and opportunities in relevant research areas. According to NIAID officials, these initiatives are developed through a structured process centered around two primary events—the annual Summer Policy Retreat and the annual Winter Program Review. NIAID staff also review their scientific areas for the latest information on burden of illness and state of scientific progress, which is used to inform the development of future initiatives. According to agency officials, NIAID staff use this information, as well as input from the scientific community, to prepare and present a concept of an initiative to NIAID's National Advisory Council, which reviews, comments on, and decides whether to approve the initiative. Once an initiative has been approved, NIAID solicits research applications through a request for application, a program announcement, or a request for proposal.
- NIDDK uses an annual process that requires NIDDK scientific program staff within the IC's divisions to review the research portfolio

and to identify research opportunities. According to NIDDK, this effort is informed by a number of factors, such as ongoing input from the extramural research and health advocacy communities and recent research advances. They said that each division then presents initiative concepts built on these research opportunities at NIDDK senior leadership meetings. The NIDDK director prioritizes the initiative concepts and determines which will move forward based on consideration of merit and other factors. These concepts go through a clearance process, including review from the NIDDK National Advisory Council. NIDDK develops funding opportunity announcements based on these identified research opportunities, such as requests for application that address specific scientific questions or diseases. In addition, NIDDK conducts divisional planning and prioritization activities during monthly meetings, retreats, and other activities, including consideration of opportunities for funds to support targeted emphasis areas.

Review and evaluation of research portfolio: Officials from the five selected ICs we interviewed stated they conduct reviews of their research portfolio to help ensure existing priorities reflect and align with current scientific opportunities, research gaps, and emerging science. This includes periodic formal program assessments of their research portfolio, which the ICs used to determine if the IC is meeting its overall priorities and goals, to maintain portfolio balance, and to make any changes to priorities over time as science evolves. Examples of portfolio review and evaluation activities include the following:

- NCI officials stated that the IC conducts portfolio analyses, which involve examining research areas NCI has funded to identify opportunities for research. Officials stated that the portfolio analysis is an iterative process that occurs continually throughout the year. One example of this portfolio analysis has involved publishing broad questions related to five themes for the research community on NCI's website and using the responses received to inform development of requests for application and program announcements published by NCI.¹⁶ Officials said they aim to generate about four new questions each year and that the questions are generally very broad and do not

¹⁶The five themes are: cancer prevention and risk; mechanisms of tumor development and recurrence; tumor detection, diagnosis, and prognosis; cancer therapy and outcomes; and clinical effectiveness.

usually address specific diseases. For example, one question recently asked how the level, type, or duration of physical activity influences cancer risk and prognosis.

- NIGMS conducts formal program evaluations to determine what benefits the program has produced overall, including scientific advances, new technologies, and cutting-edge paradigm shifts, such as changes in the understanding of human biology. In addition, officials told us that NIGMS divisions conduct an annual review, which is generally prepared for NIGMS's director, and provides information about the scientific advances that can be attributed to the work conducted in each division. This includes items such as the number of grants funded, the number of new principal investigators, the types of research conducted, and an overview of any new science performed.

While the individual ICs set their own priorities, according to NIH officials, the OD provides leadership to the ICs and helps coordinate priority setting activities, especially for efforts that involve multiple ICs. For example, NIH officials reported that the director of NIH meets with all IC directors weekly to discuss research priorities, investments, and concerns that may affect an IC or NIH overall. In addition, the Advisory Committee to the Director assists the director of NIH with making major planning and policy decisions, including those related to research priorities and the allocation of funds for major, NIH-wide projects and identifies areas that have the potential for significant improvements both within NIH and within the scientific community at large. For example, the NIH Director charged the committee with examining NIH's data needs to determine whether the agency is positioned to handle significant amounts of data and how to make these data accessible to researchers. In addition, NIH established a special division within the Office of the Director—the Division of Program Coordination, Planning, and Strategic Initiatives—to help manage large and complex research portfolios across NIH. The offices within this division organize formal discussions to obtain input from all of the IC directors as well as members of the scientific community to identify areas of significant scientific interest or need that typically span the interests of multiple ICs. NIH officials also stated that although each IC has at least one strategic plan in place, in some instances NIH has developed strategic plans for particular disease or topic areas that cross multiple ICs, such as one related to women's health research.

NIH Funding Levels Varied Widely For Selected Categories of Research, Conditions, and Diseases Corresponding to the Leading Causes of Death and Chronic Conditions

In fiscal year 2012, NIH reported funding levels that ranged widely—from \$13 million for projects in one RCDC category to more than \$5.6 billion for another—for the 40 different RCDC categories we examined. (See table 1.) We determined that these RCDC categories were the best match for the most frequent causes of death in the United States,¹⁷ the most frequent causes of death globally,¹⁸ and the most prevalent chronic conditions in the United States.¹⁹ (See app. II for an explanation of how we identified these diseases and conditions and matched them with RCDC categories.)

¹⁷D. L. Hoyert and J. Xu, National Center for Health Statistics, “Deaths: Preliminary Data for 2011,” *National Vital Statistics Reports*, vol. 61, no. 6 (Oct. 10, 2012).

¹⁸R. Lozano et al., “Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010,” *The Lancet*, vol. 380 (2012).

¹⁹CDC provided data for the most prevalent chronic conditions based on a variety of sources.

Table 1: Reported Funding for Categories in NIH’s Research, Condition, and Disease Categorization System (RCDC) Corresponding to Leading Causes of Death and Chronic Conditions, Fiscal Year 2012

NIH RCDC category corresponding to a leading cause of death or chronic condition	Fiscal year 2012 funding reported in RCDC (\$ millions)^a
Alzheimer’s disease	\$503
Arthritis	258
Asthma	229
Breast cancer	800
Cancer	5,621
Cardiovascular	2,040
Cervical cancer	112
Childhood leukemia	77
Chronic liver disease and cirrhosis	288
Chronic obstructive pulmonary disease	101
Colo-rectal cancer	302
Dental/oral and craniofacial disease	516
Diabetes	1,061
Emphysema	20
Epilepsy	156
Fibromyalgia	13
Heart disease	1,278
Heart disease - coronary heart disease	468
HIV/AIDS	3,074
Hypertension	215
Infant mortality/low birth weight	287
Influenza	251
Injury (total) accidents/adverse effects	366
Kidney disease	556
Liver cancer	73
Lung cancer	233
Lupus	108
Lymphoma	213
Malaria	152
Obesity	836
Pancreatic cancer	127
Parkinson’s disease	154

NIH RCDC category corresponding to a leading cause of death or chronic condition	Fiscal year 2012 funding reported in RCDC (\$ millions) ^a
Perinatal period - conditions originating in perinatal period	538
Pneumonia	115
Pneumonia and influenza	358
Prostate cancer	257
Septicemia	96
Stroke	310
Suicide	44
Tuberculosis	218

Source: GAO analysis of NIH data.

Notes: Leading causes of death in the United States were identified from D. L. Hoyert and J. Xu, National Center for Health Statistics, "Deaths: Preliminary Data for 2011," *National Vital Statistics Reports*, vol. 61, no. 6 (Oct. 10, 2012). Leading causes of death globally were identified from R. Lozano et al., "Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010," *The Lancet*, vol. 380 (2012). Data for the most prevalent chronic conditions were provided by the Centers for Disease Control and Prevention based on a variety of sources.

^aRCDC categories are not mutually exclusive. Because of this, NIH officials stated, RCDC is not designed to be used to determine the proportion of NIH funding specific to a given disease or condition.

NIH officials said that RCDC is the agency's official system for reporting research funding across the agency's ICs and it provides a method for reporting consistent information about NIH funding. As noted by the agency, RCDC produces standard reports across all ICs using a process that is reproducible. To facilitate this, all ICs are to use the same definitions of research, diseases, and conditions for the RCDC categories. Further, the system allows for detailed reports, including the total funding for a category as well as specific information about the projects under each category, such as the title of the project, the IC supporting the research, and the project number.

Agency officials said that the system was not designed to be able to estimate a total, non-duplicated amount of funding specific to a given disease or condition because RCDC categories are neither mutually exclusive nor exhaustive. Specifically:

- *Projects may be reported in multiple categories.* NIH officials said that the categories within the system are not mutually exclusive and therefore a project may be included in multiple categories. Officials told us that, on average, a single project may fall into five or six RCDC categories.

-
- *Categories may be contained in another category.* Some categories are inherently related and therefore an entire RCDC category can also be contained in another category. For example, the category of cancer includes other cancer categories, such as breast cancer, lung cancer, or prostate cancer, and the research funding reported in each of these categories will also be reported in the cancer research total.
 - *Categories do not exist for all diseases.* RCDC also does not capture the funding for all diseases that NIH studies. As of November 2013, RCDC publicly reported on 235 different categories, but agency officials told us that there are an additional 30 to 40 categories used for congressional reporting only, and about 50 categories on a waiting list to be developed for inclusion in the system.
 - *Not all projects that NIH funds are included.* The protocols that NIH develops for tracking funding include certain thresholds for inclusion. Therefore, a project that is only minimally related to a particular category may not be included in the funding for that category because the description of the project does not adequately match the terms defining that category. NIH officials told us that 3 to 5 percent of NIH funded research projects do not appear in any RCDC category.

Some ICs have their own systems that track and report funding within their research portfolios. Of the five selected ICs we reviewed, two had their own systems for tracking their funding.

- NCI maintains a publicly available website that communicates funding decisions across the research supported by NCI. The system was developed in 1998 and categorizes research into more than 40 specific cancer types, as well as almost 50 research topics that are not disease-specific. Funding for individual projects may be separated and reported in the NCI system by the specific types of cancers being studied. According to NIH officials, the system is limited to those research projects funded by NCI and therefore does not include information about research studies addressing cancer that are funded solely by other ICs. NCI officials told us that they use the system to report data to stakeholders, including Congress, and that the analyses they conduct based on these data enhance NCI's ability to plan and monitor its scientific investment.
- NIAID also has an internal coding system which, according to agency officials, was instituted in 1979 and codes each individual research project it funds by areas of study. Staff members manually assign codes. NIAID officials noted that projects may have multiple codes depending on the specific goals of the project, and these codes reflect

the percentage of relevance to that specific goal, such that the total values add to 100 percent. Officials noted that the system helps NIAID respond to requests for funding information that is not included in RCDC. For example, when addressing a question about how much NIAID has invested in influenza research, officials said they examine research project funding for the various subtypes of influenza such as H1N1 and avian influenzas (including H5N1 and H7N9). These subcategories are included in the internal coding system, but are not covered by RCDC. Officials noted that NIAID uses RCDC for the official budget numbers that NIH reports to Congress.

Agency Comments

We provided a draft of this report to HHS. The Department provided technical comments, which we incorporated as appropriate.

As agreed with your office, unless you publicly announce the contents of this report earlier, we plan no further distribution until 30 days from the report date. At that time, we will send copies to the Secretary of the Department of Health and Human Services, the Director of the National Institutes of Health, and other interested parties. In addition, the report will be available at no charge on the GAO website at <http://www.gao.gov>.

If you or your staff have any questions about this report, please contact me at (202) 512-7114 or kohnl@gao.gov. Contact points for our Offices of Congressional Relations and Public Affairs may be found on the last page of this report. Major contributors to this report are listed in appendix III.

Sincerely yours,



Linda T. Kohn
Director, Health Care

Appendix I: Studies about the Relationship between Research Funding and Burden of Disease

To provide information on studies about the relationship between research funding and burden of disease at the National Institutes of Health (NIH) and in other countries, we identified such studies relevant to NIH through on-line searches and we provide information on the two most recent of the studies. Additionally, for other countries, we identified published studies through a search of various databases, and we provide information from two of the more recent such studies.¹ We did not identify research funding levels in other countries.

Studies have been conducted that examine the relationship between research funding and burden of disease in the United States and other countries. Some researchers have reported that no single measure of disease burden captures the impact of various diseases and that different measures of burden may result in different conclusions about funding.

Studies on the relationship between research funding by NIH and burden of disease found varied relationships depending upon the burden of disease measures used. For example,

- A 2013 study assessed the allocation of research funds across 107 diseases using NIH's Research, Condition, and Disease Categorization system (RCDC) funding data and found a strong and statistically significant relationship between NIH funding and deaths and hospitalizations.² As a result, according to the study, the data suggest that NIH funding is responsive to these two measures of disease burden. Further, the study noted that the data were consistent with the argument that it is more feasible for NIH to respond to disease burden considerations through directed or applied research funding, such as funding for clinical trials, than through investigator-initiated basic research.
- A 2011 study to assess the correlation between NIH research funding and burden of disease using data from 2004 and 2006 found that current levels of NIH disease-specific research funding correlated modestly with U.S. disease burden.³ The study noted that there could

¹Some of the databases we searched included Medline, EMBASE, and SciSearch, among others.

²B.N. Sampat, K. Buterbaugh, and M. Perl, "New Evidence on the Allocation of NIH Funds across Diseases," *The Milbank Quarterly*, vol. 91, no. 1 (2013).

³Leslie A. Gilum et al., "NIH Disease Funding Levels and Burden of Disease," *PLoS One*, vol. 6, no. 2 (Feb. 2011). These data predate RCDC.

be a number of reasons that alignment of funding and burden of disease were not better correlated, including that basic science research has consistently accounted for 55 percent of NIH spending and it is difficult to attribute to a specific disease, contributing uncertainty to the analysis and reducing correlations. Measures of burden of disease for this study were incidence, prevalence, mortality, years of life lost to premature death (YLL), and disability-adjusted life years (DALY).⁴

Studies of research funding in other countries have also found variations in relationships between funding and burden of disease. For example,

- A 2012 study found that research expenditures by governmental agencies and charities for four of the foremost chronic diseases in the United Kingdom—cancer, coronary heart disease, stroke and dementia—was not aligned with burden of disease.⁵ Specifically, research funding for dementia and stroke was disproportionately small in comparison with funding for cancer and coronary heart disease. In this study, burden of disease was measured by prevalence and DALYs.
- A 2004 study found a significant relationship between research funding by the National Health and Medical Research Council in Australia and several measures of burden of disease,⁶ with some variations over the 6-year span reviewed in the study using different measures.⁷ Measures of burden of disease for this study were incidence, mortality, YLLs, years of life lost to disability, and DALYs.

⁴Incidence is the number of newly diagnosed cases of a disease during a given a period of time. Prevalence is how many people have a disease at any given moment in time. Disability-adjusted life years (DALY) is the sum of years of life lost due to premature death (YLL) and the years lived with a disability.

⁵R. Luengo-Fernandez, J. Leal, and A.M. Gray. “UK Research Expenditure on Dementia, Heart Disease, Stroke and Cancer: Are Levels of Spending Related to Disease Burden?” *European Journal of Neurology*, vol. 19 (2012).

⁶The National Health and Medical Research Council is the main Australian body charged with the responsibility of supporting medical and public health research and training in Australia.

⁷S. Aoun, “To What Extent Is Health and Medical Research Funding Associated with the Burden of Disease in Australia?” *Australian and New Zealand Journal of Public Health*, vol. 28, no.1 (2004).

Appendix II: Leading Causes of Death and Chronic Conditions and their Corresponding National Institutes of Health Categories

To determine the leading causes of death in the United States, we reviewed data on causes of death in 2011 that were reported by the Centers for Disease Control (CDC).¹ First, we identified the 15 leading causes of death reported by CDC. Then, we identified subcategories of those leading causes of death. To do so, we used as the cut off the number of deaths for the 15th leading cause of death—which was 18,090 deaths from pneumonitis due to solids and liquids. We included those sub-categories of causes of death, for example pneumonia, where the number of deaths reported was greater than 18,090. See table 2 for the leading causes of deaths in the United States in 2011, including the sub-categories with at least 18,090 related deaths in 2011, and the number of deaths attributed to these causes.

¹D. L. Hoyert and J. Xu, National Center for Health Statistics, “Deaths: Preliminary Data for 2011,” *National Vital Statistics Reports*, vol. 61, no. 6 (Oct. 10, 2012).

**Appendix II: Leading Causes of Death and
Chronic Conditions and their Corresponding
National Institutes of Health Categories**

Table 2: Leading Causes of Deaths in the United States, 2011

Rank	Cause of death (Subcategories)	Number of deaths
1	Diseases of heart	596,339
	Ischemic heart diseases	374,601
	Hypertensive heart disease	33,383
2	Malignant neoplasms	575,313
	Malignant neoplasms of trachea, bronchus and lung	156,614
	Malignant neoplasms of lymphoid, hematopoietic and related tissue	56,263
	Malignant neoplasms of colon, rectum and anus	52,243
	Malignant neoplasm of breast	41,271
	Malignant neoplasm of pancreas	37,371
	Malignant neoplasm of prostate	27,929
	Malignant neoplasms of liver and intrahepatic bile ducts	21,519
3	Chronic lower respiratory diseases	143,382
4	Cerebrovascular diseases	128,931
5	Accidents (unintentional injuries)	122,777
	Non-transport Accidents	85,502
	Transport Accidents	37,275
6	Alzheimer's disease	84,691
7	Diabetes mellitus	73,282
8	Influenza and pneumonia	53,667
	Pneumonia	52,136
9	Nephritis, nephrotic syndrome and nephrosis	45,731
	Renal failure	43,682
10	Intentional self-harm (suicide)	38,285
	Intentional self-harm (suicide) by discharge of firearms	19,766
	Intentional self-harm (suicide) by other and unspecified means and their sequelae	18,519
11	Septicemia	35,539
12	Chronic liver disease and cirrhosis	33,539
13	Essential hypertension and hypertensive renal disease	27,477
14	Parkinson's disease	23,107
15	Pneumonitis due to solids and liquids	18,090

Source: GAO analysis of data from Centers for Disease Control and Prevention.

Note: See D. L. Hoyert and J. Xu, National Center for Health Statistics, "Deaths: Preliminary Data for 2011," *National Vital Statistics Reports*, vol. 61, no. 6. (Oct. 10, 2012).

To determine the leading causes of death globally, we reviewed the analysis in the Global Burden of Disease Study.² We identified the 15 leading causes of death globally in 2010 that were reported in this study. See table 3 for the leading causes of deaths globally.

Table 3: Leading Causes of Deaths Globally, 2010

Rank	Cause of death
1	Ischemic heart disease
2	Stroke
3	Chronic obstructive pulmonary disease
4	Lower respiratory infections
5	Lung cancer
6	HIV/AIDS
7	Diarrheal diseases
8	Road injury
9	Diabetes
10	Tuberculosis
11	Malaria
12	Cirrhosis
13	Self-harm
14	Hypertensive heart disease
15	Preterm birth complications

Source: R. Lozano et al., "Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: a Systematic Analysis for the Global Burden of Disease Study 2010," *The Lancet*, vol. 380 (2012).

To determine the most prevalent chronic diseases and conditions in the United States, CDC provided us with a list of the 13 most prevalent chronic diseases and conditions for adults, and four subcategories. See table 4 for a list of the most prevalent chronic diseases and conditions for adults identified by CDC.

²R. Lozano et al., "Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: a Systematic Analysis for the Global Burden of Disease Study 2010," *The Lancet*, vol. 380 (2012). This study was conducted to provide reliable and timely information on the leading causes of death in populations as crucial input into health policy debates. In the study, the authors aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes.

Appendix II: Leading Causes of Death and Chronic Conditions and their Corresponding National Institutes of Health Categories

Table 4: Chronic Disease Prevalence for Adults, United States

Rank	Chronic diseases and conditions (Sub-categories)	Number of adults impacted (in 1,000s)
1	Obesity	Not reported
2	Chronic joint symptoms	68,749
3	Hypertension	58,959
4	Untreated dental caries	Not reported
5	Arthritis diagnosis	53,782
6	Asthma - ever had	29,041
7	Heart disease (total)	26,485
	Heart disease (coronary)	15,300
8	Diabetes	20,589
9	Any cancer	19,025
	Breast cancer	3,221
	Prostate cancer	2,280
	Cervical cancer	1,188
10	Asthma - still has	18,869
11	Stroke (cerebrovascular diseases)	6,171
12	Emphysema	4,680
13	Epilepsy	2,300

Source: Centers for Disease Control and Prevention.

Note: The Centers for Disease Control and Prevention provided data for the most prevalent chronic conditions based on a variety of sources.

To determine the corresponding categories from the National Institutes of Health’s (NIH) Research, Condition, and Disease Categorization system (RCDC) for the diseases and conditions that are the leading causes of death in the United States, the leading causes of death globally, and the most prevalent chronic diseases and conditions in the United States, we identified the International Classification of Diseases (ICD-10) codes associated with each of these diseases and conditions and, using their related descriptions, compared them with the RCDC category descriptions. We then provided our list of diseases, conditions, and ICD-10 codes with the corresponding RCDC categories to NIH for the agency’s review and concurrence. NIH officials confirmed most of our matches. For some of the diseases and conditions, officials noted the RCDC category that we identified was the closest match, but the category was substantially broader than the RCDC category it was selected to represent or it was substantially narrower than the RCDC category it was selected to represent. In other cases, NIH officials noted that there was

Appendix II: Leading Causes of Death and Chronic Conditions and their Corresponding National Institutes of Health Categories

not an RCDC category that was a close enough fit to the disease category we were trying to represent. See table 5 for the leading causes of death in the United States and globally, as well as the most prevalent chronic diseases and conditions, and their corresponding RCDC category or categories.

Table 5: Diseases and Conditions that Represent the Leading Causes of Death and Most Prevalent Chronic Diseases and Conditions and Corresponding Categorization

Diseases and conditions	Leading cause of U.S. deaths	Leading cause of global deaths	Most prevalent U.S chronic diseases/ conditions	Research, Condition, and Disease Categorization system (RCDC)
Accidents (unintentional injuries)	x			Injury (total) accidents/adverse effects
Alzheimer's disease	x			Alzheimer's disease
Arthritis (diagnosis)			x	Arthritis; lupus; fibromyalgia
Asthma - ever had			x	Asthma
Asthma - still has			x	Asthma
Cancer (any)			x	Cancer
Cancer of the breast			x	Breast cancer
Cancer of the cervix			x	Cervical cancer
Cancer of the lung		x		Lung cancer
Cancer of the prostate			x	Prostate cancer
Cerebrovascular disease	x			Stroke
Chronic joint symptoms			x	No RCDC match
Chronic liver disease and cirrhosis	x			Chronic liver disease and cirrhosis
Chronic lower respiratory diseases	x			Asthma; chronic obstructive pulmonary disease; emphysema
Chronic obstructive pulmonary disease		x		Chronic obstructive pulmonary disease; emphysema
Cirrhosis		x		Chronic liver disease and cirrhosis
Diabetes mellitus	x			Diabetes
Diabetes		x	x	Diabetes
Diarrheal diseases		x		No RCDC match
Diseases of the heart	x			Cardiovascular
Emphysema			x	Emphysema
Epilepsy			x	Epilepsy
Essential hypertension and hypertensive renal disease	x			Hypertension

Appendix II: Leading Causes of Death and Chronic Conditions and their Corresponding National Institutes of Health Categories

Diseases and conditions	Leading cause of U.S. deaths	Leading cause of global deaths	Most prevalent U.S chronic diseases/ conditions	Research, Condition, and Disease Categorization system (RCDC)
Heart disease (coronary)			x	Heart disease – coronary heart disease
Heart disease (total)			x	Heart disease
HIV/AIDS		x		HIV/AIDS
Hypertension			x	Hypertension
Hypertensive heart disease	x	x		Hypertension ^a
Intentional self-harm (suicide)	x			Suicide
Intentional self-harm (suicide) by discharge of firearms	x			No RCDC match
Intentional self-harm (suicide) by other and unspecified means and their sequelae	x			No RCDC match
Ischemic heart disease	x	x		Heart disease – coronary heart disease ^a
Lower respiratory infections		x		Pneumonia: influenza ^b
Malaria		x		Malaria
Malignant neoplasms	x			Cancer
Malignant neoplasms of breast	x			Breast cancer
Malignant neoplasms of colon, rectum, and anus	x			Colo-rectal cancer
Malignant neoplasms of liver, and intrahepatic bile ducts	x			Liver cancer
Malignant neoplasms of lymphoid, hematopoietic and related tissue	x			Lymphoma; childhood leukemia
Malignant neoplasms of pancreas	x			Pancreatic cancer
Malignant neoplasms of prostate	x			Prostate cancer
Malignant neoplasms of trachea, bronchus, and lung	x			Lung cancer
Nephritis, nephrotic syndrome, and nephrosis	x			Kidney disease
Non-transport accidents	x			No RCDC match
Obesity			x	Obesity
Parkinson's disease	x			Parkinson's disease
Pneumonia	x			Pneumonia
Pneumonitis due to solids and liquids	x			No RCDC match
Pneumonia and influenza	x			Pneumonia and influenza
Pre-term birth complications		x		Infant mortality/low birth weight; perinatal period – conditions originating in perinatal period

Appendix II: Leading Causes of Death and Chronic Conditions and their Corresponding National Institutes of Health Categories

Diseases and conditions	Leading cause of U.S. deaths	Leading cause of global deaths	Most prevalent U.S chronic diseases/ conditions	Research, Condition, and Disease Categorization system (RCDC)
Renal failure	x			Kidney disease
Road injury		x		No RCDC match
Self-harm		x		Suicide
Septicemia	x			Septicemia
Stroke		x		Stroke
Stroke (cerebrovascular disease)			x	Stroke
Transport accidents	x			No RCDC match
Tuberculosis		x		Tuberculosis
Untreated dental caries			x	Dental/oral and craniofacial disease ^a

Source: GAO analysis of Centers for Disease Control and Prevention data, Global Burden of Disease Study, and National Institutes of Health data.

^aNIH noted that while this RCDC category was the closest match, it is substantially broader than the disease or condition it was selected to represent.

^bNIH noted that while this RCDC category was the closest match, it is substantially narrower than the disease or condition it was selected to represent.

Appendix III: GAO Contact and Staff Acknowledgments

GAO Contact

Linda T. Kohn, Director, (202) 512-7114 or kohnl@gao.gov

Staff Acknowledgments

In addition to the contact name above, Karen Doran (Assistant Director), George Bogart, Adrienne Daniels, Carolyn Feis Korman, Cathy Hamann, Natalie Herzog, Amy Leone, and Andrea Richardson made key contributions to this report.

GAO's Mission

The Government Accountability Office, the audit, evaluation, and investigative arm of Congress, exists to support Congress in meeting its constitutional responsibilities and to help improve the performance and accountability of the federal government for the American people. GAO examines the use of public funds; evaluates federal programs and policies; and provides analyses, recommendations, and other assistance to help Congress make informed oversight, policy, and funding decisions. GAO's commitment to good government is reflected in its core values of accountability, integrity, and reliability.

Obtaining Copies of GAO Reports and Testimony

The fastest and easiest way to obtain copies of GAO documents at no cost is through GAO's website (<http://www.gao.gov>). Each weekday afternoon, GAO posts on its website newly released reports, testimony, and correspondence. To have GAO e-mail you a list of newly posted products, go to <http://www.gao.gov> and select "E-mail Updates."

Order by Phone

The price of each GAO publication reflects GAO's actual cost of production and distribution and depends on the number of pages in the publication and whether the publication is printed in color or black and white. Pricing and ordering information is posted on GAO's website, <http://www.gao.gov/ordering.htm>.

Place orders by calling (202) 512-6000, toll free (866) 801-7077, or TDD (202) 512-2537.

Orders may be paid for using American Express, Discover Card, MasterCard, Visa, check, or money order. Call for additional information.

Connect with GAO

Connect with GAO on [Facebook](#), [Flickr](#), [Twitter](#), and [YouTube](#). Subscribe to our [RSS Feeds](#) or [E-mail Updates](#). Listen to our [Podcasts](#). Visit GAO on the web at www.gao.gov.

To Report Fraud, Waste, and Abuse in Federal Programs

Contact:

Website: <http://www.gao.gov/fraudnet/fraudnet.htm>

E-mail: fraudnet@gao.gov

Automated answering system: (800) 424-5454 or (202) 512-7470

Congressional Relations

Katherine Siggerud, Managing Director, siggerudk@gao.gov, (202) 512-4400, U.S. Government Accountability Office, 441 G Street NW, Room 7125, Washington, DC 20548

Public Affairs

Chuck Young, Managing Director, youngc1@gao.gov, (202) 512-4800 U.S. Government Accountability Office, 441 G Street NW, Room 7149 Washington, DC 20548

